[
  {
    "ts": "2025-11-04T05:38:32+00:00",
    "headline": "5 Revealing Analyst Questions From Regeneron’s Q3 Earnings Call",
    "summary": "Regeneron’s third quarter results were well received by the market, reflecting strong execution in its commercial portfolio and key products. Management attributed the positive momentum to double-digit sales growth for Dupixent, Libtayo, and EYLEA HD, despite flat overall sales. CEO Leonard Schleifer highlighted that Dupixent’s broadening indications and robust uptake across geographies remained a primary growth driver, while EYLEA HD benefited from increased physician demand, partially offset b",
    "url": "https://finance.yahoo.com/news/5-revealing-analyst-questions-regeneron-053832748.html",
    "source": "StockStory",
    "provider": "yfinance",
    "raw": {
      "id": "8d6e13d5-6da7-3e28-a378-20d08adfb493",
      "content": {
        "id": "8d6e13d5-6da7-3e28-a378-20d08adfb493",
        "contentType": "STORY",
        "title": "5 Revealing Analyst Questions From Regeneron’s Q3 Earnings Call",
        "description": "",
        "summary": "Regeneron’s third quarter results were well received by the market, reflecting strong execution in its commercial portfolio and key products. Management attributed the positive momentum to double-digit sales growth for Dupixent, Libtayo, and EYLEA HD, despite flat overall sales. CEO Leonard Schleifer highlighted that Dupixent’s broadening indications and robust uptake across geographies remained a primary growth driver, while EYLEA HD benefited from increased physician demand, partially offset b",
        "pubDate": "2025-11-04T05:38:32Z",
        "displayTime": "2025-11-04T05:38:32Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/stockstory_922/863b7649ab1334021118a8518d7e40cd",
          "originalWidth": 1400,
          "originalHeight": 700,
          "caption": "REGN Cover Image",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/E5YeVaDzgHlFxvDwMx9gpg--~B/aD03MDA7dz0xNDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/stockstory_922/863b7649ab1334021118a8518d7e40cd.cf.webp",
              "width": 1400,
              "height": 700,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/6HLp77Q1Eazwpb8zaGf6Xg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/stockstory_922/863b7649ab1334021118a8518d7e40cd.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "StockStory",
          "url": "https://stockstory.org/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/5-revealing-analyst-questions-regeneron-053832748.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/5-revealing-analyst-questions-regeneron-053832748.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "REGN"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]